Breakthrough in Heart Failure therapy: LCZ696 combining ACE-Nepriylisin inhibition

Sandeep Lahiry¹, Rajasree Sinha², Shouvik Choudhury³, Ayan Mukherjee⁴

¹,³,⁴ Post Graduate Trainee, Department of Pharmacology, Institute of Post Graduate Medical Education and Research, ²Post Graduate Trainee, Department of Pediatrics, Medical College and Hospital, Kolkata, West Bengal, India

Submitted: 29-09-2016 Revised: 14-10-2016 Published: 01-01-2017

ABSTRACT

Background: Current Heart failure (HF) pharmacotherapy has been unsatisfactory in halting disease progression completely. Aims and Objective: To evaluate the role of LCZ696, a recent FDA-approved ACE -Neprilysin inhibitor (ARNi) in the management of HF from available trial data. Materials and Methods: Trial data on ‘LCZ696’ was assessed using PubMed search. Methodological filters were applied to limit retrieval to ‘Randomized Controlled Trial’ (RCT). Bibliographic databases with ‘Human’ data were selected. Trial data comparing ‘LCZ696’ to other drugs or placebo were accessed in full-text. CONSORT guidelines were used for quality assessment. Incomplete methodology, results in abstract form, duplicate publications were excluded. Data extraction forms were piloted and used to obtain uniform quality of data. Results: Multi-centric trial data (n=2) revealed noticeable benefits with ‘LCZ696’ in patients with HF with reduced ejection fraction (HFrEF), reducing cardiovascular death or hospitalization for HF by 20%; cardiovascular deaths by 20%; hospitalization for HF by 21%; all cause mortality reduction by 20% as compared to ACE inhibitors (ACEi) (PARADIGM-HF; n=8442). Angioedema was notably absent. Decrease in high sensitivity Troponin-T, improvement in N-terminal-pro-BNP and left atrial dimensions suggested reduction of myocardial injury in HF with preserved ejection fraction (HFpEF) (PARAMOUNT trial; n=301). Conclusion: There is convincing evidence of the role of novel ARNi (Angiotensin receptor – Nepriylisin Inhibitors) in HF pharmacotherapy. Its role in other cardiovascular conditions merits assessment.

Key words: LCZ696, Neprilysin, Heart failure

INTRODUCTION

Currently, renin-angiotensin-aldosterone system (RAAS) blockade remains the mainstay of HF pharmacotherapy. However, combination of RAAS blockade and ‘Nepriylisin’ inhibition, an enzyme that degrades natriuretic peptides (NPs), has recently emerged as a potentially superior treatment strategy. On 7th July 2015, Valsartan-Sacubitril (LCZ696) received FDA’s priority approval for use in HF. In retrospect, the approval was based on data from the Prospective Comparison of ARNi [angiotensin receptor-neprilisin inhibitor] with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF; NCT01035255) trial, when it was presented at the European Society of Cardiology (ESC) 2014 Congress at Barcelona, Spain.²

MATERIALS AND METHODS

Literature search

Online literature was assessed using PubMed search. Search strategy consisted of controlled vocabulary and keywords. Main search concepts were ‘LCZ696’, ‘Heart failure’ and ‘Nepriylisin’. Methodological filters were applied to limit retrieval to ‘Randomized Controlled Trial’ (RCT). Retrieval was limited to ‘English’ and ‘Human’.
**Selection criteria & methodology**

Reviewers independently screened citations of preliminary selected RCTs (n=6) and current clinical practice guidelines on HF. In cases of insufficient information, full-text article with abstract was ordered. Only full-text publications were included. Additional information was accessed using Google Scholar search engine.

**Exclusion criteria**

Studies with incomplete methodology; presented preliminary results in abstract form; duplicate publications, editorials were excluded.

**Data extraction strategy**

Data extraction forms were piloted and independent extraction of clinical effectiveness data for each article was undertaken. Relevant features & outcomes from the included studies were tabulated. Any disagreement between reviewers was discussed until consensus was reached.

**Critical appraisal of individual studies**

Quality of RCTs was assessed following CONSORT guidelines.

**Data analysis method**

Because of clinical heterogeneity across the selected studies, a formal analysis was not conducted. The findings are described using a narrative approach.

**RESULTS**

Electronic literature search yielded a total of 76 citations, of which 25 citations were excluded, and 51 potentially relevant articles were shortlisted. 12 articles were available for full-text review, of which 6 were RCTs. Complete data on 2 RCTs primarily concerning to HF therapy were included (PARAMOUNT and PARADIGM-HF).

The PARADIGM-HF study demonstrated the favorable effect of LCZ696 that was seen in all subgroups examined, including those based on age, sex, weight, race, NYHA class, presence or absence of reduced kidney function, prior hospitalization etc. Significant benefits were recorded in patients with NYHA class II-IV Systolic HF using ‘LCZ696’ over ACE inhibitors (ACEi), reducing cardiovascular death or hospitalization for HF by 20%, cardiovascular deaths by 20% , hospitalization for Heart Failure by 21% and all-cause mortality reduction by 20%. Patients were followed up for an average of 27 months. The study revealed LCZ696 to be superior to enalapril in a well-managed cohort of patients with HF, 93% with β-adrenergic blockers therapy and 55.6% on mineralocorticoid receptor antagonists (MRA).

The PARAMOUNT (Prospective Comparison of ARNi with ARB on Management of Heart Failure with Preserved Ejection Fraction: NCT01920711) trial compared LCZ696 with valsartan in patients (n = 301) having HF with preserved ejection fraction (HFpEF). There was a significant decrease in NT-proBNP (N-terminal of Brain natriuretic peptide) levels in the LCZ696 group at 12 weeks; however, the difference was insignificant at 36 weeks. Furthermore, there was no change in LV size, function, or mass; diastolic function; NYHA class; or quality-of-life scores at 12 weeks.

**DISCUSSION**

Natriuretic peptides (NP) are hormones responsible for maintaining normal sodium and fluid homeostasis. Their release is triggered by increased myocardial filling pressures. Their beneficial role include vasodilation, increased glomerular filtration rate (GFR) and reduced renal release of renin, in addition to natriuresis and diuresis. NPs are broken down by an enzyme neutral endopeptidase (NEP) or ‘Neprilysin’.

Neprilysin, a metalloprotease (zinc-dependent), cleaves hydrophobic peptide residues at the amino side and inactivates numerous peptides. It also degrades the amyloid-beta peptide whose abnormal misfolding and aggregation in neural tissue implicated to be causative of Alzheimer’s disease. Degradation of vasoactive substances like peptides, glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin and adrenomedullin by Neprilysin, reduces deleterious neurohormonal activation, subsequent vasoconstriction, sodium retention and maladaptive remodeling.

Increased salutary NP actions also have a beneficial role in HF. Neprilysin is known to hydrolyze NPs, therefore its inhibition would mitigate risk of cardiovascular disease. When the left ventricle and myocardium is stressed as in HF, there is an increase in diastolic pressure wall stress; the myocytes pro-BNP which is cleaved in two subunits in the plasma: the inactive N-terminal fragment and the active C-terminal fragment, BNP. In the PARADIGM-HF trial, in patients with HFpEF, LCZ696 caused reduction in NT-proBNP to a greater extent than did valsartan at 12 weeks and was better tolerated.

Inhibiting Neprilysin had been a therapeutic target for several compounds that had previously been tested in cardiovascular disease, including ecallatril, candoxatril, omapatrilat and other NEPI-ACEi (vasopeptidase-inhibitors). Although these drugs were initially tested in their role in hypertension and/or HF, lack of efficacy and side effects (Angioedema) led to discontinuation of their development.
LCZ696 (Valsartan-Sacubitril) is a novel ARNi developed and approved for use in HF. It has six molecules of the Neprilysin inhibitor Sacubitril (AHU-377), six molecules of anionic form of Valsartan bound together in a single crystalline complex. Valsartan moiety blocks the angiotensin II receptor type 1 (AT1) and thereby causing vasodilation and increased excretion of sodium and water via the kidneys (by reducing aldosterone production). The latter mechanism also causes a reduction in blood volume. Sacubitril, a prodrug, is activated to LBQ657 by de-ethylation via esterases. LBQ657 causes inhibition of enzyme Neprilysin, which is responsible for the degradation of ANP & BNP, two blood pressure lowering peptides that work mainly by reducing blood volume. Because this molecule is made in a fixed ratio (1:1), the 97 mg of Sacubitril provides about 90% Neprilysin inhibition. It has been proposed as a twice daily regimen, costing $12.50/day (Entresto®-Novartis) in U.S.A, can be taken regardless of food intake. Experts are enthusiastic about the prospects of the ARNi, believed to be representing the future cornerstone of chronic HF therapy. The new Canadian Heart Failure guidelines have already been updated to include the drug in its recommendations.

Though recent guidelines have started incorporating ARNi in HFrEF pharmacotherapy, complete status of LCZ696 in management of newly diagnosed HFpEF patients remains yet unclear. Though expected to show better compliance and favourable adverse effect profile, complete data on safety and tolerability profile will be assessed further following its use in a broad range of patients with HF with different symptomatic spectrum. Long term trials may still be needed to consolidate its decisive role.

ACKNOWLEDGEMENT

We are extremely thankful to the faculty of the Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata for their kind permission to carry out this study.

Key message

LCZ696 opens up a new class of novel ARNi, which seeks to exploit clinical efficacy of combined RAAS-blockade and NEPi-mediated natriuretic peptide augmentation with improved clinical safety profile & seems to challenge existing evidence-based medical therapy in HF.

REFERENCES

1. Gibney M. “Novartis’ new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril/valsartan)”. FierceBiotech. 2015.

Authors Contribution:
SL - Reviewed the literature and manuscript preparation; SC - Collected data, review of literature and helped in preparing first draft of manuscript; AM - Literature search and critical revision of the manuscript; RS - Concept of study and review of study.

Source of Support: Nil. Conflict of Interest: None declared.